Teva gains final US approval for generic Aciphex

5 March 2007

The US Food and Drug Administration has granted final approval for Israeli firm Teva Pharmaceutical Industries' Abbreviated New Drug Application for rabeprazole sodium delayed-release tablets, 20mg.

Teva's rabeprazole product is the AB-rated generic equivalent of Eisai's acid pump inhibitor Aciphex, which had annual sales of approximately $1.3 billion, based on IMS Health sales data.

As one of the first companies to file an ANDA containing a paragraph IV certification for this product, Teva says it has been awarded a 180-day period of marketing exclusivity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight